Literature DB >> 17722007

The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis.

Luiz Vicente F da Silva Filho1, Adriana F Tateno, Kátia M Martins, Ana Carolina Azzuz Chernishev, Doroti de Oliveira Garcia, Maria Haug, Christoph Meisner, Joaquim C Rodrigues, Gerd Döring.   

Abstract

BACKGROUND: Early diagnosis of Pseudomonas aeruginosa colonization/infection in patients with cystic fibrosis (CF) using microbiological culturing methods may be difficult. Serology and polymerase chain reaction (PCR) may be useful techniques for early detection of P. aeruginosa in children with CF.
METHODS: A cross-sectional analysis comparing results obtained by three different methods for P. aeruginosa identification was performed in 87 CF patients with a mean age of 9.7 years. Microbiological culturing and PCR targeting the algD GDP mannose dehydrogenase gene of P. aeruginosa were performed in sputum or oropharyngeal swabs samples, and serum antibodies against three P. aeruginosa antigens (elastase, alkaline protease, and exotoxin A) were assessed once.
RESULTS: It was possible to isolate P. aeruginosa by culture in samples from 42 patients (48.2%), while PCR was positive in 53 (60.9%) patients. Serology was positive in 38 patients (43.6%), with a higher positivity for elastase (37.9%), followed by alkaline protease (29.9%) and exotoxin A (19.5%). The difference among the three isolated methods was not statistically significant. The combination of PCR + serology was significantly superior to single methods, to PCR + culture and also to culture + serology.
CONCLUSIONS: PCR identified a higher number of patients with P. aeruginosa than serology and conventional culture, but the difference did not reach statistical significance. Any of the combination methods that included PCR resulted in significantly statistical differences in relation to isolated microbiological or serology methods, but not to the PCR method alone, suggesting that PCR may be the main additive method for P. aeruginosa identification. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722007     DOI: 10.1002/ppul.20686

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  18 in total

1.  Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.

Authors:  Zhe Hui Hoo; Elizabeth Coates; Chin Maguire; Hannah Cantrill; Nadia Shafi; Edward F Nash; Angela McGowan; Stephen J Bourke; William G Flight; Thomas V Daniels; Julia A Nightingale; Mark I Allenby; Rachael Curley; Martin J Wildman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-18       Impact factor: 3.267

Review 2.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

3.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 4.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

5.  Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.

Authors:  Lucas R Hoffman; Hemantha D Kulasekara; Julia Emerson; Laura S Houston; Jane L Burns; Bonnie W Ramsey; Samuel I Miller
Journal:  J Cyst Fibros       Date:  2008-10-29       Impact factor: 5.482

6.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

Review 7.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

Review 8.  Biomarkers in Cystic Fibrosis Lung Disease - A Review.

Authors:  Ioana Mihaiela Ciuca; Paula Marian; Marc Monica
Journal:  Rom J Anaesth Intensive Care       Date:  2020-10-11

9.  Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.

Authors:  D Hayes; P M Farrell; Z Li; S E West
Journal:  Pediatr Pulmonol       Date:  2010-01

10.  Comparison of the sensitivity of culture, PCR and quantitative real-time PCR for the detection of Pseudomonas aeruginosa in sputum of cystic fibrosis patients.

Authors:  Pieter Deschaght; Thierry De Baere; Leen Van Simaey; Sabine Van Daele; Frans De Baets; Daniel De Vos; Jean-Paul Pirnay; Mario Vaneechoutte
Journal:  BMC Microbiol       Date:  2009-11-29       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.